The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY). Designed for patients aged 12 and older ...

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...

The Food and Drug Administration’s top vaccine official, Peter Marks, resigned on Friday, citing what he called Health and ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent prot ...

US gene therapy company bluebird bio (Nasdaq: BLUE) has confirmed receipt of an unsolicited non-binding written proposal from ...

What is your sentiment on Nasdaq?

Spotify Technology S.A.-3.80% $116.5B ...

Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education.